Re-appintment of M S K A & Associates LLP, Chartered Accountants as the Statutory Auditors of the Company for a second term of five consecutive years from the conclusion of the 37th Annual ....
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies Ltd held a Board Meeting on May 9, 2026, approving audited standalone and consolidated financial results for FY2026. Consolidated revenue from operations stood at ₹7,457.57 million (up 17.1% YoY from ₹6,369.10 million), with net profit after tax of ₹1,736.08 million (up 29.6% YoY from ₹1,339.74 million). The Board recommended a final dividend of ₹1.35 per equity share (67.5% payout, face value ₹2), payable from the second day after the 37th AGM, and deferred an interim dividend citing capital preservation for strategic actions. MSKA & Associates LLP was reappointed as Statutory Auditors for a second consecutive 5-year term through the 42nd AGM. Mr. Mukund Kabra was reappointed as Whole-time Director for 5 years (April 2027–March 2032) and Mr. Pradip Bhailal Shah was appointed as Additional Independent Director for a 5-year term from June 12, 2026. The company also allotted 49,350 equity shares under the ESOP 2022 scheme, increasing paid-up capital to ₹22,39,52,300 across 11,19,76,150 shares. The auditors issued an unmodified opinion. The consolidated balance sheet shows total assets of ₹18,387.61 million and total equity of ₹16,831.22 million.
Strong financial performance with ~30% PAT growth and healthy dividend payout; auditor continuity provides stability. Capital preservation stance for strategic actions signals potential M&A or corporate actions ahead, which could be a re-rating catalyst for the stock.